Long noncoding RNA DHRS4 antisense RNA 1 suppresses osteosarcoma cell proliferation and promotes apoptosis through a competitive endogenous RNA mechanism
- PMID: 39843945
- PMCID: PMC11754436
- DOI: 10.1038/s41598-025-87246-7
Long noncoding RNA DHRS4 antisense RNA 1 suppresses osteosarcoma cell proliferation and promotes apoptosis through a competitive endogenous RNA mechanism
Abstract
Osteosarcoma (OS) is the most common primary malignant bone tumor. Recent evidence suggests that the novel long noncoding RNA DHRS4 antisense RNA 1 (DHRS4-AS1) serves an important role in cancer progression and metastasis. However, its function and molecular mechanism in OS remain largely unknown. In the present study, DHRS4-AS1 expression was detected in OS cells by quantitative PCR. Gain- and loss-of-function experiments were conducted to study the effects of DHRS4-AS1 on the proliferation and apoptosis of OS cells. The potential mechanism of DHRS4-AS1 was examined through bioinformatics analysis and rescue experiments. DHRS4-AS1 was downregulated in OS cell lines. DHRS4-AS1 depletion promoted proliferation and inhibited apoptosis in OS cells, whereas DHRS4-AS1 overexpression had the opposite effects. Further research suggested that DHRS4-AS1 inhibited OS progression by regulating the microRNA-362-5p/aminopeptidase puromycin sensitive axis. The present findings suggested that DHRS4-AS1 may serve as a potential therapeutic target for OS.
Keywords: DHRS4-AS1; Long noncoding RNAs; MiR-362-5p; NPEPPS; Osteosarcoma.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Consent for publication: Not applicable. Ethics approval: The study was approved by the Ethics Committee of the Zhujiang Hospital of Southern Medical University (LAEC-2022-043).
Figures
References
-
- Sadykova, L. R. et al. Epidemiology and risk factors of Osteosarcoma. Cancer Invest.38, 259–269. 10.1080/07357907.2020.1768401 (2020). - PubMed
-
- Chen, C. et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett.500, 1–10. 10.1016/j.canlet.2020.12.024 (2021). - PubMed
-
- Heymann, M. F., Brown, H. K. & Heymann, D. Drugs in early clinical development for the treatment of osteosarcoma. Expert Opin. Investig. Drugs. 25, 1265–1280. 10.1080/13543784.2016.1237503 (2016). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
